E
VYGR icon

Ergoteles’s Voyager Therapeutics VYGR Stock Holding History

Ergoteles’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-24,379
Closed -$149K – 1789
2022
Q4 		$149K Buy
+24,379
New +$139K 0.01% 1152
2022
Q3 		– Sell
-58,152
Closed -$344K – 2027
2022
Q2 		$344K Buy
+58,152
New +$393K 0.01% 1034
2021
Q4 		– Sell
-109,211
Closed -$287K – 1625
2021
Q3 		$287K Sell
109,211
-8,989
-8% -$29.2K 0.01% 823
2021
Q2 		$488K Buy
+118,200
New +$536K 0.01% 819

Other funds holding VYGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ergoteles's VYGR Position: Q1 2023 in Review

Ergoteles sold out of Voyager Therapeutics (VYGR) in Q1 2023, closing a stake of 24,379 shares — an estimated $149K sold.

Ergoteles first reported a position in VYGR in Q2 2021 and held it in 4 quarters. The position peaked at $488K in Q2 2021. 81 funds tracked by Wall St. Rank hold VYGR as of Q1 2023.

  • Ergoteles reported no remaining Voyager Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 24,379 Voyager Therapeutics shares in Q1 2023, an estimated $149K.
  • Ergoteles first reported a position in Voyager Therapeutics in Q2 2021 and held it in 4 quarters.
  • Ergoteles's Voyager Therapeutics position peaked at $488K in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.